Pathogenically, SCN2A variants alter voltage-gated sodium channel activity, leading to early infantile epileptic encephalopathy, whereas PAH and GNPAT variants disrupt amino acid and peroxisomal metabolism, respectively. This evidence concerns the gene GNPAT and pulmonary arterial hypertension.